2026/2027 Elite Test Bank and
Clinical Mentor Report:
Pharmacology for Nurses (7th
Edition)
Part 0: The Navigator
● Section I: Foundational Syntax & Application (Questions 1–15)
○ Focus: 2026/2027 FDA Approvals, Pharmacodynamics, ISMP Hard Decks.
● Section II: Professional Simulation (Questions 16–40)
○ Focus: UT Austin/Dell Seton Clinical Scenarios, Immediate Action Protocols,
Critical Rescue.
● Section III: Grandmaster Synthesis (Questions 41–66)
○ Focus: High-Stakes Multi-System Failure, AHA, GOLD, KDIGO, and ADA 2026
Guideline Integration.
Part I: The Primer
Mastering this pathophysiologic approach to pharmacology is the definitive threshold separating
task-oriented novices from elite clinical decision-makers. High-level professional success
demands the seamless integration of cellular pharmacodynamics with the absolute latest
2026/2027 evidence-based regulatory frameworks to avert patient mortality.
● The ISMP Zero Protocol: Trailing zeros (e.g., 5.0 mg) are strictly forbidden; leading
zeros (e.g., 0.5 mg) are legally mandatory. Patient weights must be obtained exclusively
via metric-only scales (kg).
● AHA 2026 HFrEF Protocol: Immediate, simultaneous initiation of Quadruple Therapy
(ARNI, Beta-blocker, MRA, SGLT2i) is mandatory; sequential titration is obsolete.
● GOLD 2026 COPD Matrix: A single moderate exacerbation immediately reclassifies a
patient to high-risk Category E, mandating dual long-acting bronchodilator therapy.
● KDIGO 2026 Anemia Standard: Proactive intravenous iron is prioritized for hemodialysis
patients with a strict withholding ceiling of Ferritin >700 ng/mL or TSAT \ge 40%.
● ADA 2026 Adipocentric Shift: GLP-1 or dual GIP/GLP-1 receptor agonists are primary
interventions for Type 2 Diabetes with MASH, HFpEF, or obesity, independent of baseline
A1C.
Part II: The Elite Test Bank
Section I: Foundational Syntax & Application
,Q1: A practitioner is preparing a dose of the novel 2025 FDA-approved analgesic, suzetrigine,
for a patient with severe acute postoperative pain. Which statement represents the MOST
ACCURATE pathophysiological rationale for selecting this medication over a traditional opioid
agonist? A) Suzetrigine competitively antagonizes mu-opioid receptors in the central nervous
system, reversing respiratory depression while maintaining analgesia. B) Suzetrigine provides
profound analgesia by selectively inhibiting NaV1.8 sodium channels exclusively in peripheral
nociceptive neurons, completely bypassing the central nervous system and eliminating addiction
potential. C) Suzetrigine is a nonselective cyclooxygenase inhibitor that reduces peripheral
prostaglandin synthesis with a zero percent risk of gastrointestinal hemorrhage. D) Suzetrigine
induces central sedation by enhancing gamma-aminobutyric acid (GABA) transmission, thereby
dulling the patient's psychological perception of pain.
● The Answer: B (Suzetrigine provides profound analgesia by selectively inhibiting NaV1.8
sodium channels exclusively in peripheral nociceptive neurons, completely bypassing the
central nervous system and eliminating addiction potential.)
● Distractor Analysis:
○ A is incorrect: This describes an opioid antagonist like naloxone, not an analgesic.
○ C is incorrect: This describes traditional NSAIDs, which carry well-documented
gastrointestinal and renal risks.
○ D is incorrect: This describes benzodiazepines or gabapentinoids, which cause
systemic CNS depression.
The Mentor's Analysis: The 2025 approval of suzetrigine revolutionized acute pain
management. By targeting the NaV1.8 voltage-gated sodium channel—which is expressed
solely on peripheral pain-sensing neurons—it blocks the pain signal before it reaches the spinal
cord or brain. This provides opioid-level efficacy without the fatal CNS side effects of respiratory
depression or dopamine-driven euphoria. Professional Intuition: Isolate the peripheral signal;
protect the central system.
Q2: Under the 2026 ISMP Targeted Medication Safety Best Practices, a nurse is preparing to
administer vinCRIStine to an oncology patient. Which preparation and administration protocol is
STRICTLY MANDATED to avert a fatal sentinel event? A) Dispense the drug in a specialized
intrathecal syringe with a highly visible warning label to ensure proper routing. B) Administer the
drug via rapid intravenous push directly into a central venous catheter to prevent peripheral
extravasation. C) Dilute the drug in a minibag containing a volume too large for intrathecal
administration (e.g., 50 mL for adults) and administer strictly via the intravenous route. D)
Reconstitute the drug at the bedside using a sterile water pour bottle to guarantee immediate
freshness before intravenous administration.
● The Answer: C (Dilute the drug in a minibag containing a volume too large for intrathecal
administration (e.g., 50 mL for adults) and administer strictly via the intravenous route.)
● Distractor Analysis:
○ A is incorrect: Vinca alkaloids are universally fatal if given intrathecally. Dispensing
them in any syringe allows for this catastrophic route mix-up.
○ B is incorrect: While it must go IV, ISMP strictly forbids syringe dispensing to
eliminate the physical possibility of an intrathecal push.
○ D is incorrect: ISMP Best Practices strictly prohibit the use of sterile water pour
bottles for IV preparation due to the risk of fatal hemolysis.
The Mentor's Analysis: Human error is inevitable; system design must account for it.
Dispensing vinCRIStine in a syringe relies on the clinician's vigilance to prevent an intrathecal
injection. The 2026 standard removes vigilance from the equation entirely. By placing the drug in
a 50 mL minibag, you make it physically impossible to connect it to a spinal needle.
,Professional Intuition: Engineer the physical environment so that the deadly mistake becomes
mechanically impossible.
Q3: According to the 2026 American Heart Association (AHA) guidelines for Heart Failure with
reduced Ejection Fraction (HFrEF), which pharmacological strategy represents the REQUIRED
INITIAL approach for a newly diagnosed, hemodynamically stable patient? A) Initiate an ACE
inhibitor, titrate to the maximum tolerated dose over 4 weeks, and then introduce a beta-blocker.
B) Simultaneously initiate low-dose Quadruple Therapy consisting of an ARNI, an
evidence-based Beta-blocker, an MRA, and an SGLT2 inhibitor. C) Prescribe a loop diuretic to
clear volume overload and delay neurohormonal blockade until the patient's creatinine
normalizes. D) Initiate a sodium-glucose cotransporter-2 (SGLT2) inhibitor only if the patient has
a documented history of Type 2 Diabetes Mellitus.
● The Answer: B (Simultaneously initiate low-dose Quadruple Therapy consisting of an
ARNI, an evidence-based Beta-blocker, an MRA, and an SGLT2 inhibitor.)
● Distractor Analysis:
○ A is incorrect: Sequential, historical titration leaves the patient vulnerable to sudden
cardiac death and disease progression while waiting months to achieve full therapy.
○ C is incorrect: Loop diuretics treat symptoms but provide zero mortality benefit.
Delaying Guideline-Directed Medical Therapy (GDMT) is clinical negligence.
○ D is incorrect: SGLT2 inhibitors are foundational for HFrEF survival, completely
independent of the patient's glycemic status.
The Mentor's Analysis: The "Fantastic Four" of GDMT target distinctly different, yet
synergistic, pathophysiological pathways (neurohormonal, metabolic, and renal). The 2026
standard dictates that getting the patient on all four pillars rapidly, even at low doses, yields a
73% relative risk reduction in mortality. Professional Intuition: Breadth of therapy saves lives;
depth of therapy (titration) optimizes them. Establish all four pillars immediately.
Q4: A patient is prescribed etripamil for the outpatient management of Paroxysmal
Supraventricular Tachycardia (PSVT). What is the MOST CRITICAL patient education point
regarding the administration of this novel 2025 FDA-approved medication? A) "Swallow the
tablet whole with a full glass of water at the exact onset of palpitations." B) "Administer one
spray into each nostril while sitting down; if symptoms persist after 10 minutes, administer a
second complete dose." C) "Inject the pre-filled syringe into the anterolateral thigh at the first
sign of a racing heart." D) "Place the rapid-dissolving film under your tongue and avoid drinking
liquids for 30 minutes."
● The Answer: B ("Administer one spray into each nostril while sitting down; if symptoms
persist after 10 minutes, administer a second complete dose.")
● Distractor Analysis:
○ A is incorrect: Oral calcium channel blockers are too slow for acute PSVT
conversion and suffer from the first-pass effect.
○ C is incorrect: Etripamil is not a subcutaneous injection.
○ D is incorrect: This describes the administration of Anaphylm (sublingual
epinephrine), not etripamil.
The Mentor's Analysis: Etripamil (Cardamyst) is an intranasal calcium channel blocker
designed to bypass the hospital ED and put PSVT conversion directly into the patient's hands.
Because it is a rapid-acting vasodilator and AV-node blocker, syncope is a primary risk.
Therefore, educating the patient to administer the dose while seated is a non-negotiable safety
parameter. Professional Intuition: Empower the patient with rapid-onset rescue drugs, but
secure their physical safety against orthostatic collapse first.
Q5: Based on the GOLD 2026 framework, a patient with Chronic Obstructive Pulmonary
, Disease (COPD) who experienced a single moderate exacerbation requiring outpatient systemic
corticosteroids last year must IMMEDIATELY be classified into which group and receive which
baseline pharmacotherapy? A) Group A; short-acting beta-agonist (SABA) as needed. B) Group
B; long-acting muscarinic antagonist (LAMA) monotherapy. C) Group E; dual therapy with a
LABA and LAMA. D) Group E; triple therapy with a LABA, LAMA, and Inhaled Corticosteroid
(ICS) regardless of biomarker status.
● The Answer: C (Group E; dual therapy with a LABA and LAMA.)
● Distractor Analysis:
○ A and B are incorrect: The 2026 update strictly establishes that a single moderate
exacerbation automatically elevates the patient out of Groups A and B due to the
massive increase in future cardiovascular risk.
○ D is incorrect: While the patient is in Group E, an ICS is only indicated if the
peripheral blood eosinophil count crosses the specific inflammatory threshold of \ge
300 cells/µL.
The Mentor's Analysis: COPD is no longer viewed as a static mechanical obstruction; it is a
dynamic inflammatory disease. The 2026 guidelines lowered the threshold because data proved
that a single moderate exacerbation dramatically accelerates lung decline and 30-day
myocardial infarction risk. Reclassifying them to Group E forces proactive dual-bronchodilation
to achieve absolute disease stability. Professional Intuition: One strike means you escalate.
Never wait for the second exacerbation to optimize maintenance therapy.
Q6: Under the 2026 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, a patient
with Chronic Kidney Disease (CKD) on hemodialysis presents with a hemoglobin of 9.5 g/dL, a
ferritin of 450 ng/mL, and a Transferrin Saturation (TSAT) of 28%. Which pharmacological
intervention is MOST APPROPRIATE? A) Withhold all iron therapy because the ferritin exceeds
100 ng/mL, indicating adequate stores. B) Administer proactive intravenous (IV) iron to
maximize erythropoiesis and reduce ESA dose requirements. C) Initiate an oral iron supplement
to avoid the risk of IV-induced anaphylaxis. D) Immediately initiate a red blood cell transfusion to
rapidly correct the anemia.
● The Answer: B (Administer proactive intravenous (IV) iron to maximize erythropoiesis
and reduce ESA dose requirements.)
● Distractor Analysis:
○ A is incorrect: Ferritin <100 ng/mL is the systemic iron deficiency threshold for
non-dialysis patients. Dialysis patients require a higher ceiling (up to 700 ng/mL).
○ C is incorrect: Oral iron is largely ineffective in hemodialysis patients due to chronic
inflammation and hepcidin-mediated gut blockade.
○ D is incorrect: Transfusions are an absolute last resort due to the risk of HLA
alloimmunization, which destroys future kidney transplant viability.
The Mentor's Analysis: The 2026 KDIGO update relies on the PIVOTAL trial data, which
proved that proactive IV iron in hemodialysis safely raises hemoglobin and lowers the need for
Erythropoiesis-Stimulating Agents (ESAs), directly reducing cardiovascular mortality. You push
IV iron until the safety ceiling of 700 ng/mL Ferritin or 40% TSAT is breached. Professional
Intuition: In dialysis, the gut is closed to iron. Bypass the gut, fill the iron tank proactively, and
starve the ESA requirement.
Q7: A practitioner prescribes brensocatib for a patient with severe non-cystic fibrosis
bronchiectasis (NCFB). To ensure comprehensive 2026 safety monitoring, the nurse must
PRIORITIZE referrals to which two ancillary specialties? A) Cardiology and Ophthalmology. B)
Dermatology and Dentistry. C) Nephrology and Audiology. D) Hepatology and Podiatry.
● The Answer: B (Dermatology and Dentistry.)
Clinical Mentor Report:
Pharmacology for Nurses (7th
Edition)
Part 0: The Navigator
● Section I: Foundational Syntax & Application (Questions 1–15)
○ Focus: 2026/2027 FDA Approvals, Pharmacodynamics, ISMP Hard Decks.
● Section II: Professional Simulation (Questions 16–40)
○ Focus: UT Austin/Dell Seton Clinical Scenarios, Immediate Action Protocols,
Critical Rescue.
● Section III: Grandmaster Synthesis (Questions 41–66)
○ Focus: High-Stakes Multi-System Failure, AHA, GOLD, KDIGO, and ADA 2026
Guideline Integration.
Part I: The Primer
Mastering this pathophysiologic approach to pharmacology is the definitive threshold separating
task-oriented novices from elite clinical decision-makers. High-level professional success
demands the seamless integration of cellular pharmacodynamics with the absolute latest
2026/2027 evidence-based regulatory frameworks to avert patient mortality.
● The ISMP Zero Protocol: Trailing zeros (e.g., 5.0 mg) are strictly forbidden; leading
zeros (e.g., 0.5 mg) are legally mandatory. Patient weights must be obtained exclusively
via metric-only scales (kg).
● AHA 2026 HFrEF Protocol: Immediate, simultaneous initiation of Quadruple Therapy
(ARNI, Beta-blocker, MRA, SGLT2i) is mandatory; sequential titration is obsolete.
● GOLD 2026 COPD Matrix: A single moderate exacerbation immediately reclassifies a
patient to high-risk Category E, mandating dual long-acting bronchodilator therapy.
● KDIGO 2026 Anemia Standard: Proactive intravenous iron is prioritized for hemodialysis
patients with a strict withholding ceiling of Ferritin >700 ng/mL or TSAT \ge 40%.
● ADA 2026 Adipocentric Shift: GLP-1 or dual GIP/GLP-1 receptor agonists are primary
interventions for Type 2 Diabetes with MASH, HFpEF, or obesity, independent of baseline
A1C.
Part II: The Elite Test Bank
Section I: Foundational Syntax & Application
,Q1: A practitioner is preparing a dose of the novel 2025 FDA-approved analgesic, suzetrigine,
for a patient with severe acute postoperative pain. Which statement represents the MOST
ACCURATE pathophysiological rationale for selecting this medication over a traditional opioid
agonist? A) Suzetrigine competitively antagonizes mu-opioid receptors in the central nervous
system, reversing respiratory depression while maintaining analgesia. B) Suzetrigine provides
profound analgesia by selectively inhibiting NaV1.8 sodium channels exclusively in peripheral
nociceptive neurons, completely bypassing the central nervous system and eliminating addiction
potential. C) Suzetrigine is a nonselective cyclooxygenase inhibitor that reduces peripheral
prostaglandin synthesis with a zero percent risk of gastrointestinal hemorrhage. D) Suzetrigine
induces central sedation by enhancing gamma-aminobutyric acid (GABA) transmission, thereby
dulling the patient's psychological perception of pain.
● The Answer: B (Suzetrigine provides profound analgesia by selectively inhibiting NaV1.8
sodium channels exclusively in peripheral nociceptive neurons, completely bypassing the
central nervous system and eliminating addiction potential.)
● Distractor Analysis:
○ A is incorrect: This describes an opioid antagonist like naloxone, not an analgesic.
○ C is incorrect: This describes traditional NSAIDs, which carry well-documented
gastrointestinal and renal risks.
○ D is incorrect: This describes benzodiazepines or gabapentinoids, which cause
systemic CNS depression.
The Mentor's Analysis: The 2025 approval of suzetrigine revolutionized acute pain
management. By targeting the NaV1.8 voltage-gated sodium channel—which is expressed
solely on peripheral pain-sensing neurons—it blocks the pain signal before it reaches the spinal
cord or brain. This provides opioid-level efficacy without the fatal CNS side effects of respiratory
depression or dopamine-driven euphoria. Professional Intuition: Isolate the peripheral signal;
protect the central system.
Q2: Under the 2026 ISMP Targeted Medication Safety Best Practices, a nurse is preparing to
administer vinCRIStine to an oncology patient. Which preparation and administration protocol is
STRICTLY MANDATED to avert a fatal sentinel event? A) Dispense the drug in a specialized
intrathecal syringe with a highly visible warning label to ensure proper routing. B) Administer the
drug via rapid intravenous push directly into a central venous catheter to prevent peripheral
extravasation. C) Dilute the drug in a minibag containing a volume too large for intrathecal
administration (e.g., 50 mL for adults) and administer strictly via the intravenous route. D)
Reconstitute the drug at the bedside using a sterile water pour bottle to guarantee immediate
freshness before intravenous administration.
● The Answer: C (Dilute the drug in a minibag containing a volume too large for intrathecal
administration (e.g., 50 mL for adults) and administer strictly via the intravenous route.)
● Distractor Analysis:
○ A is incorrect: Vinca alkaloids are universally fatal if given intrathecally. Dispensing
them in any syringe allows for this catastrophic route mix-up.
○ B is incorrect: While it must go IV, ISMP strictly forbids syringe dispensing to
eliminate the physical possibility of an intrathecal push.
○ D is incorrect: ISMP Best Practices strictly prohibit the use of sterile water pour
bottles for IV preparation due to the risk of fatal hemolysis.
The Mentor's Analysis: Human error is inevitable; system design must account for it.
Dispensing vinCRIStine in a syringe relies on the clinician's vigilance to prevent an intrathecal
injection. The 2026 standard removes vigilance from the equation entirely. By placing the drug in
a 50 mL minibag, you make it physically impossible to connect it to a spinal needle.
,Professional Intuition: Engineer the physical environment so that the deadly mistake becomes
mechanically impossible.
Q3: According to the 2026 American Heart Association (AHA) guidelines for Heart Failure with
reduced Ejection Fraction (HFrEF), which pharmacological strategy represents the REQUIRED
INITIAL approach for a newly diagnosed, hemodynamically stable patient? A) Initiate an ACE
inhibitor, titrate to the maximum tolerated dose over 4 weeks, and then introduce a beta-blocker.
B) Simultaneously initiate low-dose Quadruple Therapy consisting of an ARNI, an
evidence-based Beta-blocker, an MRA, and an SGLT2 inhibitor. C) Prescribe a loop diuretic to
clear volume overload and delay neurohormonal blockade until the patient's creatinine
normalizes. D) Initiate a sodium-glucose cotransporter-2 (SGLT2) inhibitor only if the patient has
a documented history of Type 2 Diabetes Mellitus.
● The Answer: B (Simultaneously initiate low-dose Quadruple Therapy consisting of an
ARNI, an evidence-based Beta-blocker, an MRA, and an SGLT2 inhibitor.)
● Distractor Analysis:
○ A is incorrect: Sequential, historical titration leaves the patient vulnerable to sudden
cardiac death and disease progression while waiting months to achieve full therapy.
○ C is incorrect: Loop diuretics treat symptoms but provide zero mortality benefit.
Delaying Guideline-Directed Medical Therapy (GDMT) is clinical negligence.
○ D is incorrect: SGLT2 inhibitors are foundational for HFrEF survival, completely
independent of the patient's glycemic status.
The Mentor's Analysis: The "Fantastic Four" of GDMT target distinctly different, yet
synergistic, pathophysiological pathways (neurohormonal, metabolic, and renal). The 2026
standard dictates that getting the patient on all four pillars rapidly, even at low doses, yields a
73% relative risk reduction in mortality. Professional Intuition: Breadth of therapy saves lives;
depth of therapy (titration) optimizes them. Establish all four pillars immediately.
Q4: A patient is prescribed etripamil for the outpatient management of Paroxysmal
Supraventricular Tachycardia (PSVT). What is the MOST CRITICAL patient education point
regarding the administration of this novel 2025 FDA-approved medication? A) "Swallow the
tablet whole with a full glass of water at the exact onset of palpitations." B) "Administer one
spray into each nostril while sitting down; if symptoms persist after 10 minutes, administer a
second complete dose." C) "Inject the pre-filled syringe into the anterolateral thigh at the first
sign of a racing heart." D) "Place the rapid-dissolving film under your tongue and avoid drinking
liquids for 30 minutes."
● The Answer: B ("Administer one spray into each nostril while sitting down; if symptoms
persist after 10 minutes, administer a second complete dose.")
● Distractor Analysis:
○ A is incorrect: Oral calcium channel blockers are too slow for acute PSVT
conversion and suffer from the first-pass effect.
○ C is incorrect: Etripamil is not a subcutaneous injection.
○ D is incorrect: This describes the administration of Anaphylm (sublingual
epinephrine), not etripamil.
The Mentor's Analysis: Etripamil (Cardamyst) is an intranasal calcium channel blocker
designed to bypass the hospital ED and put PSVT conversion directly into the patient's hands.
Because it is a rapid-acting vasodilator and AV-node blocker, syncope is a primary risk.
Therefore, educating the patient to administer the dose while seated is a non-negotiable safety
parameter. Professional Intuition: Empower the patient with rapid-onset rescue drugs, but
secure their physical safety against orthostatic collapse first.
Q5: Based on the GOLD 2026 framework, a patient with Chronic Obstructive Pulmonary
, Disease (COPD) who experienced a single moderate exacerbation requiring outpatient systemic
corticosteroids last year must IMMEDIATELY be classified into which group and receive which
baseline pharmacotherapy? A) Group A; short-acting beta-agonist (SABA) as needed. B) Group
B; long-acting muscarinic antagonist (LAMA) monotherapy. C) Group E; dual therapy with a
LABA and LAMA. D) Group E; triple therapy with a LABA, LAMA, and Inhaled Corticosteroid
(ICS) regardless of biomarker status.
● The Answer: C (Group E; dual therapy with a LABA and LAMA.)
● Distractor Analysis:
○ A and B are incorrect: The 2026 update strictly establishes that a single moderate
exacerbation automatically elevates the patient out of Groups A and B due to the
massive increase in future cardiovascular risk.
○ D is incorrect: While the patient is in Group E, an ICS is only indicated if the
peripheral blood eosinophil count crosses the specific inflammatory threshold of \ge
300 cells/µL.
The Mentor's Analysis: COPD is no longer viewed as a static mechanical obstruction; it is a
dynamic inflammatory disease. The 2026 guidelines lowered the threshold because data proved
that a single moderate exacerbation dramatically accelerates lung decline and 30-day
myocardial infarction risk. Reclassifying them to Group E forces proactive dual-bronchodilation
to achieve absolute disease stability. Professional Intuition: One strike means you escalate.
Never wait for the second exacerbation to optimize maintenance therapy.
Q6: Under the 2026 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, a patient
with Chronic Kidney Disease (CKD) on hemodialysis presents with a hemoglobin of 9.5 g/dL, a
ferritin of 450 ng/mL, and a Transferrin Saturation (TSAT) of 28%. Which pharmacological
intervention is MOST APPROPRIATE? A) Withhold all iron therapy because the ferritin exceeds
100 ng/mL, indicating adequate stores. B) Administer proactive intravenous (IV) iron to
maximize erythropoiesis and reduce ESA dose requirements. C) Initiate an oral iron supplement
to avoid the risk of IV-induced anaphylaxis. D) Immediately initiate a red blood cell transfusion to
rapidly correct the anemia.
● The Answer: B (Administer proactive intravenous (IV) iron to maximize erythropoiesis
and reduce ESA dose requirements.)
● Distractor Analysis:
○ A is incorrect: Ferritin <100 ng/mL is the systemic iron deficiency threshold for
non-dialysis patients. Dialysis patients require a higher ceiling (up to 700 ng/mL).
○ C is incorrect: Oral iron is largely ineffective in hemodialysis patients due to chronic
inflammation and hepcidin-mediated gut blockade.
○ D is incorrect: Transfusions are an absolute last resort due to the risk of HLA
alloimmunization, which destroys future kidney transplant viability.
The Mentor's Analysis: The 2026 KDIGO update relies on the PIVOTAL trial data, which
proved that proactive IV iron in hemodialysis safely raises hemoglobin and lowers the need for
Erythropoiesis-Stimulating Agents (ESAs), directly reducing cardiovascular mortality. You push
IV iron until the safety ceiling of 700 ng/mL Ferritin or 40% TSAT is breached. Professional
Intuition: In dialysis, the gut is closed to iron. Bypass the gut, fill the iron tank proactively, and
starve the ESA requirement.
Q7: A practitioner prescribes brensocatib for a patient with severe non-cystic fibrosis
bronchiectasis (NCFB). To ensure comprehensive 2026 safety monitoring, the nurse must
PRIORITIZE referrals to which two ancillary specialties? A) Cardiology and Ophthalmology. B)
Dermatology and Dentistry. C) Nephrology and Audiology. D) Hepatology and Podiatry.
● The Answer: B (Dermatology and Dentistry.)
